Integrated Diagnostics Holdings PLC (IDHC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Integrated Diagnostics Holdings PLC (IDHC) has a cash flow conversion efficiency ratio of 0.051x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($197.02 Million) by net assets ($3.83 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See IDHC net asset quality score to measure how much of total assets are equity-financed.
Integrated Diagnostics Holdings PLC - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Integrated Diagnostics Holdings PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Integrated Diagnostics Holdings PLC's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Integrated Diagnostics Holdings PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Integrated Diagnostics Holdings PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hibiscus Petroleum BHD
KLSE:5199
|
-0.186x |
|
Qumei Furniture Group Co Ltd
SHG:603818
|
0.062x |
|
Hyliion Holdings Corp.
NYSE MKT:HYLN
|
-0.052x |
|
Shandong Cynda Chemcial Co Ltd
SHG:603086
|
-0.022x |
|
Xiamen R&T Plumbing Technology Co Ltd
SHE:002790
|
0.021x |
|
Incar Financial Service Co. Ltd.
KQ:211050
|
0.307x |
|
Jiangsu Tianmu Lake Tourism Co Ltd
SHG:603136
|
0.043x |
|
Acco Brands Corporation
NYSE:ACCO
|
0.005x |
Annual Cash Flow Conversion Efficiency for Integrated Diagnostics Holdings PLC (2012–2024)
The table below shows the annual cash flow conversion efficiency of Integrated Diagnostics Holdings PLC from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see IDHC market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.50 Billion | $1.57 Billion | 0.448x | +155.65% |
| 2023-12-31 | $3.10 Billion | $543.66 Million | 0.175x | +105.54% |
| 2022-12-31 | $2.45 Billion | $208.73 Million | 0.085x | -89.50% |
| 2021-12-31 | $2.79 Billion | $2.27 Billion | 0.812x | +123.33% |
| 2020-12-31 | $2.43 Billion | $882.51 Million | 0.364x | +23.09% |
| 2019-12-31 | $2.36 Billion | $697.41 Million | 0.295x | +27.51% |
| 2018-12-31 | $2.40 Billion | $556.31 Million | 0.232x | +33.04% |
| 2017-12-31 | $2.31 Billion | $403.07 Million | 0.174x | +0.47% |
| 2016-12-31 | $2.30 Billion | $398.66 Million | 0.173x | +77.37% |
| 2015-12-31 | $1.94 Billion | $189.86 Million | 0.098x | -39.86% |
| 2014-12-31 | $1.86 Billion | $301.59 Million | 0.163x | +51.14% |
| 2013-12-31 | $1.95 Billion | $209.29 Million | 0.108x | -65.18% |
| 2012-12-31 | $2.07 Billion | $639.10 Million | 0.309x | -- |
About Integrated Diagnostics Holdings PLC
Integrated Diagnostics Holdings plc operates as a consumer healthcare company that provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron… Read more